41 275

Cited 4 times in

Clinical stage drugs targeting inhibitor of apoptosis proteins purge episomal Hepatitis B viral genome in preclinical models

Authors
 Michelle P Clark  ;  Thao Huynh  ;  Shringar Rao  ;  Liana Mackiewicz  ;  Hugh Mason  ;  Shahla Romal  ;  Michael D Stutz  ;  Sang H Ahn  ;  Linda Earnest  ;  Vitina Sozzi  ;  Margaret Littlejohn  ;  Bang M Tran  ;  Norbert Wiedemann  ;  Elizabeth Vincan  ;  Joseph Torresi  ;  Hans J Netter  ;  Tokameh Mahmoudi  ;  Peter Revill  ;  Marc Pellegrini  ;  Gregor Ebert 
Citation
 CELL DEATH & DISEASE, Vol.12(7) : 641, 2021-06 
Journal Title
CELL DEATH & DISEASE
Issue Date
2021-06
MeSH
Animals ; Antiviral Agents / pharmacology* ; Azocines / pharmacology* ; Benzhydryl Compounds / pharmacology* ; Disease Models, Animal ; Genome, Viral* ; Hep G2 Cells ; Hepatitis B / drug therapy* ; Hepatitis B / metabolism ; Hepatitis B / pathology ; Hepatitis B / virology ; Hepatitis B virus / drug effects* ; Hepatitis B virus / genetics ; Hepatocytes / drug effects* ; Hepatocytes / metabolism ; Hepatocytes / pathology ; Hepatocytes / virology ; Host-Pathogen Interactions ; Humans ; Inhibitor of Apoptosis Proteins / antagonists & inhibitors* ; Inhibitor of Apoptosis Proteins / metabolism ; Liver / drug effects* ; Liver / metabolism ; Liver / pathology ; Liver / virology ; Mice, Inbred C57BL ; Mice, Knockout ; Molecular Targeted Therapy ; Organoids ; Thiazoles / pharmacology* ; Tumor Necrosis Factor-alpha / genetics ; Tumor Necrosis Factor-alpha / metabolism ; Virus Replication / drug effects
Abstract
A major unmet clinical need is a therapeutic capable of removing hepatitis B virus (HBV) genome from the liver of infected individuals to reduce their risk of developing liver cancer. A strategy to deliver such a therapy could utilize the ability to target and promote apoptosis of infected hepatocytes. Presently there is no clinically relevant strategy that has been shown to effectively remove persistent episomal covalently closed circular HBV DNA (cccDNA) from the nucleus of hepatocytes. We used linearized single genome length HBV DNA of various genotypes to establish a cccDNA-like reservoir in immunocompetent mice and showed that clinical-stage orally administered drugs that antagonize the function of cellular inhibitor of apoptosis proteins can eliminate HBV replication and episomal HBV genome in the liver. Primary human liver organoid models were used to confirm the clinical relevance of these results. This study underscores a clinically tenable strategy for the potential elimination of chronic HBV reservoirs in patients.
Files in This Item:
T202126073.pdf Download
DOI
10.1038/s41419-021-03924-0
Appears in Collections:
1. College of Medicine (의과대학) > Dept. of Internal Medicine (내과학교실) > 1. Journal Papers
Yonsei Authors
Ahn, Sang Hoon(안상훈) ORCID logo https://orcid.org/0000-0002-3629-4624
URI
https://ir.ymlib.yonsei.ac.kr/handle/22282913/190441
사서에게 알리기
  feedback

qrcode

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.

Browse

Links